Precision Strike: Neurogene Champions Direct-to-Brain Gene Therapy

NEW YORK, NY – April 28, 2026 – As the field of genetic medicine races to address devastating neurological disorders, the question is no longer just what to deliver, but how. Neurogene Inc. is placing a strategic bet on a direct-to-brain delivery method, preparing to argue that the technique is a crucial key to unlocking the full potential of its gene therapy for Rett syndrome.

The New York-based biotechnology company announced it will present a detailed therapeutic rationale for intracerebroventricular (ICV) administration at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May. The presentation aims to demystify the neurosurgical procedure and position it as a "growing standard" for delivering genetic medicine directly to the central nervous system (CNS), a move that could have significant implications for its lead candidate, NGN-401.

The Delivery Dilemma: Targeting the Brain

Treating complex neurological diseases like Rett syndrome presents a formidable challenge: the blood-brain barrier, a protective shield that prevents most drugs and therapies from reaching their intended targets. To overcome this, companies have turned to direct CNS delivery, primarily using two routes: intrathecal-lumbar (IT-L) injection into the lower spinal canal or intracerebroventricular (ICV) administration directly into the brain's fluid-filled ventricles.

Neurogene is championing the latter, arguing that for a pervasive disorder like Rett syndrome, which affects multiple brain regions, achieving the broadest possible distribution of the therapy is paramount. The company’s preclinical data, set to be a cornerstone of its ASGCT presentation, shows that ICV delivery of NGN-401 resulted in significantly greater biodistribution across the brain compared to IT-L administration. Research indicates this can translate to 10 to 100 times more therapeutic material reaching critical cortical regions.

While ICV delivery involves a more invasive neurosurgical procedure than a lumbar puncture, Neurogene and its collaborators emphasize that it is a well-established and routinely performed technique. The company's presentation will highlight that clinical safety in CNS gene therapy appears to be driven more by the therapeutic product itself than the delivery route, with ICV showing a generally well-tolerated profile. The one-time nature of gene therapy makes the initial choice of administration route a critical decision for maximizing long-term clinical benefit.

NGN-401: A Multifaceted Approach to Rett Syndrome

Neurogene's commitment to ICV delivery is deeply intertwined with the specific design of NGN-401. The investigational therapy is engineered to address the root cause of Rett syndrome, a severe neurodevelopmental disorder caused by mutations in the MECP2 gene. Unlike some competing therapies that use a shortened "mini-gene," NGN-401 is the only clinical candidate designed to deliver the full-length human MECP2 gene.

This approach is coupled with the company's proprietary EXACT™ transgene regulation technology. A major challenge in MECP2 gene therapy is the risk of toxicity from overexpressing the MeCP2 protein. The EXACT™ platform is designed to act as a sophisticated internal control system, ensuring that the therapeutic gene's expression is tightly controlled on a cell-by-cell basis to remain within a safe and effective range.

By combining a full-gene payload and a precise regulation system with a delivery method designed for maximum brain coverage, Neurogene is pursuing a comprehensive strategy aimed at restoring function across the wide spectrum of symptoms associated with Rett syndrome, from motor and communication deficits to breathing and autonomic dysfunction.

Clinical Promise and Regulatory Momentum

The company's confidence in its strategy is bolstered by encouraging early results. Interim data from its Phase 1/2 clinical trial have shown that participants treated with NGN-401 experienced "durable, multidomain developmental milestone gains" and continued to acquire new skills over time. The therapy, delivered via ICV at the planned registrational dose of 1E15 vector genomes, has been generally well-tolerated.

“Our selection of ICV delivery for NGN-401 was informed by robust preclinical data that showed broader brain and nervous system biodistribution compared to IT-L, critical for a CNS-mediated disease such as Rett syndrome,” stated Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. “We believe the data we have reported from our ongoing Phase 1/2 trial reinforce our choice of ICV delivery, with participants demonstrating durable, multidomain developmental milestone gains over time and a safety profile... that supports continued advancement of NGN‑401 in our Embolden™ registrational trial.”

This progress has not gone unnoticed by global regulators. NGN-401 has amassed an impressive collection of special designations, including Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Fast Track from the U.S. Food and Drug Administration. It was also selected for the FDA's START Pilot Program, designed to accelerate development for rare disease therapies. Similar priority designations have been granted by European and UK authorities, signaling strong institutional belief in the therapy's potential to address a significant unmet medical need.

Navigating a Competitive Landscape

Neurogene’s push to validate ICV delivery comes as the therapeutic landscape for Rett syndrome becomes increasingly active. The company's primary gene therapy competitor, Taysha Gene Therapies, is advancing its candidate, TSHA-102, which uses the alternative IT-L delivery route and a mini-gene version of MECP2. The differing strategies on both the therapeutic payload and the delivery method set the stage for a critical comparison as more clinical data becomes available from both programs.

These gene therapies are also entering a market that now includes an approved treatment, Acadia Pharmaceuticals' Trofinetide, a small-molecule drug that addresses symptoms but does not correct the underlying genetic defect. Gene therapies like NGN-401 represent a fundamentally different approach, offering the potential for a one-time, transformative treatment that targets the root cause of the disease.

By bringing its case for ICV delivery to the scientific community at ASGCT, led by a renowned expert like Dr. Daniel J. Curry of Texas Children's Hospital, Neurogene is not just defending a technical choice. It is making a strategic move to build consensus around its "biology-first" approach and position NGN-401 as a potential best-in-class therapy, arguing that the right delivery route is the essential first step toward achieving a meaningful and lasting impact for patients.